ACE2 and asthma: This risk reduction may be attributed, in part, to lower interferon levels in patients with asthma—which could attenuate the cytokine storm that occurs in severe COVID-19, or to the downregulation of angiotensin-converting-enzyme-2 (ACE-2) receptors (one of the binding sites for SARS-CoV-2) in patients with T2-high asthma [40].